Status update regarding application to start clinical study with ALZ-101
Alzinova announces today that the documentation required for the application to start the planned Phase 1b clinical study with the drug candidate ALZ-101 will be ready during June. As such, the first patient first dose (FPFD) will not be administered during this quarter as previously communicated.The study is instead expected to start during the third quarter and we also plan to administer the FPFD in the same quarter, provided that the Covid-19 situation in Finland allows for that. "Today's announcement means a slight change to what we have previously communicated, which is of course